# Comprehensive Cancer Center Support Grant

> **NIH NIH P30** · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2024 · $215,332

## Abstract

PROJECT SUMMARY:
 Approximately 1.2 million people are currently living with HIV (PLWH) in the United States. These individuals
are at an elevated risk for various cancers, particularly B-cell non-Hodgkin lymphomas (BCLs), such as diffuse
large B-cell lymphoma and Burkitt lymphoma. These lymphomas often display comorbidity with Epstein-Barr
virus infection (EBV). The use of combinatorial antiretroviral therapy (cART) has been shown to effectively control
HIV replication, leading to restored immune function and decreased cancer rates in PLWH. Moreover, the latest
developments in cancer treatment, along with cART, have significantly increased the success rates for PLWH
battling cancer. Despite such advancements in treatment and improved survival rates, effectively managing
cancers in PLWH demands a comprehensive approach – one that takes into consideration the specific traits of
these malignancies when in the presence of HIV.
 HIV and EBV, which solely infect human hosts, create a unique obstacle in the development of in vivo models
for assessing potential cancer therapies. Humanized mice with a functional human blood system offer a valuable
model for studying immunotherapeutic approaches for BCLs under HIV and EBV co-infection. Through our
recent single-cell transcriptomics analysis of humanized mice, we have discovered that the NSG-SGM3 mouse
outperforms the standard NSG mouse in its ability to mimic various types of human blood cells found in human
peripheral blood. Developing a murine model with a realistic human tumor microenvironment largely relies on
this critical factor. This model is integral in evaluating the effectiveness of immune-based cancer therapies and
monitoring immunological changes throughout treatment. The proposed study aims to confirm the effectiveness
of new CAR-T cell approaches for treating BCLs in the presence of HIV while examining its immunological impact
using a humanized NSG-SGM3 mouse model.

## Key facts

- **NIH application ID:** 11065935
- **Project number:** 3P30CA013148-51S3
- **Recipient organization:** UNIVERSITY OF ALABAMA AT BIRMINGHAM
- **Principal Investigator:** Barry P Sleckman
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $215,332
- **Award type:** 3
- **Project period:** 1997-03-28 → 2027-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11065935

## Citation

> US National Institutes of Health, RePORTER application 11065935, Comprehensive Cancer Center Support Grant (3P30CA013148-51S3). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/11065935. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*